How to Get Tresiba in Alaska: Prescriptions, Telehealth, and Pharmacy Options

What Is Tresiba and Why Clinicians Prescribe It

Insulin degludec is an ultra-long-acting basal insulin with a half-life exceeding 25 hours and a duration of action beyond 42 hours, which produces a flatter, more predictable glucose-lowering profile than older basal insulins. The FDA approved insulin degludec in September 2015 under the brand name Tresiba in both U-100 and U-200 concentrations [1]. Novo Nordisk manufactures it as a prefilled FlexTouch pen.

The pharmacokinetic advantage matters clinically. Because degludec forms multi-hexamer chains at the injection site, absorption is slow and steady. The SWITCH 1 trial (N=501, type 1 diabetes) showed a statistically significant 11% reduction in overall hypoglycemia rate compared with insulin glargine U-100 during the maintenance period (rate ratio 0.89 to 95% CI 0.82 to 0.97, P<0.05) [2]. The SWITCH 2 trial (N=721, type 2 diabetes) found a 30% reduction in nocturnal confirmed hypoglycemia versus glargine U-100 [3].

The DEVOTE cardiovascular outcomes trial (N=7,637, median follow-up 2.0 years) established that insulin degludec is non-inferior to insulin glargine U-100 for three-point MACE (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke): hazard ratio 0.91 (95% CI 0.78 to 1.06, P<0.001 for non-inferiority) [4]. The American Diabetes Association 2024 Standards of Care state that "insulin degludec and insulin glargine U-300 are associated with lower rates of hypoglycemia than first-generation basal insulins and may be preferred in people at high risk of hypoglycemia" [5].

Tresiba is approved for adults and children aged 1 year and older with type 1 diabetes, and for adults with type 2 diabetes [1]. Starting dose guidance from the FDA label specifies one-third of total daily insulin for type 1 patients transitioning from another basal insulin [1].

Alaska-Specific Prescribing Rules for Tresiba

Alaska law permits telehealth prescribing for schedule-exempt medications including insulin. Tresiba is not a controlled substance, so no DEA registration is required for the prescribing provider beyond their standard state medical license [6]. Under Alaska Statute § 08.64.107, a valid patient-provider relationship can be established via synchronous audio-video telehealth without a prior in-person visit, provided the clinician documents a sufficient history and review of systems [6].

Nurse practitioners in Alaska hold full practice authority under AS 08.68.410, meaning they can prescribe Tresiba independently without physician oversight [7]. Physician assistants prescribe under a supervision agreement with a collaborating physician, though in practice the requirement is largely administrative for established telehealth platforms [7]. Medical doctors and doctors of osteopathic medicine prescribe under standard licensure, and international medical graduates practicing in Alaska must hold a full unrestricted Alaska medical license to issue telehealth prescriptions to Alaska patients.

Any provider prescribing Tresiba to an Alaska resident via telehealth must be licensed in the state of Alaska. Licensure in another state does not suffice. Patients should confirm this before booking an appointment, because prescriptions written by an out-of-state-only provider cannot be filled at Alaska pharmacies or through mail-order to an Alaska address.

How to Get a Tresiba Prescription Step by Step

Getting a prescription involves four concrete steps.

Step 1: Choose a prescriber. You may see a primary care physician, endocrinologist, or nurse practitioner in Alaska, or use a telehealth platform licensed in the state. Telehealth visits for basal insulin initiation typically run 30 to 45 minutes. The provider will review your HbA1c history, current medications, kidney function (eGFR), and any hypoglycemia episodes.

Step 2: Complete required labs. Before initiating Tresiba, most prescribers order a fasting plasma glucose, HbA1c, comprehensive metabolic panel (to assess renal and hepatic function), and a complete blood count. The ADA recommends HbA1c testing at least twice yearly in patients meeting treatment goals and quarterly if therapy is changed [5]. Remote telehealth providers in Alaska frequently use LabCorp or Quest Diagnostics, both of which have draw sites in Anchorage, Fairbanks, and Juneau, and offer courier pickup in some rural areas. Results are typically returned within 24 to 72 hours.

Step 3: Obtain and send the prescription. Once issued, the prescription goes directly to your chosen pharmacy via e-prescribe, or a PDF is sent if you use a compounding pharmacy. Confirm the provider sends the correct concentration (U-100 or U-200) and quantity, since Tresiba U-200 pens contain 300 units per pen (3 mL at 200 U/mL) versus 300 units per pen for U-100 (3 mL at 100 U/mL). Concentration errors lead to dispensing mistakes [1].

Step 4: Manage insurance or pay out of pocket. Tresiba's list price is approximately $330 to $450 per package of five pens depending on concentration. Novo Nordisk's savings card reduces cost to $99 per month for eligible commercially insured patients. The Novo Nordisk Patient Assistance Program provides free insulin to qualifying uninsured patients earning under 400% of the federal poverty level [8].

Telehealth Providers Prescribing Tresiba in Alaska

Multiple national telehealth platforms hold Alaska prescribing authority, including endocrinology-focused services. When evaluating a platform, confirm three things: the prescribing provider holds an active Alaska license, the platform uses a HIPAA-compliant video system for the initial visit, and the platform can route prescriptions to a pharmacy that delivers to your zip code. Rural Alaska zip codes, including those served only by small air carriers, can receive mail-order insulin if the pharmacy ships with temperature-controlled packaging (gel packs or insulated pouches rated for 72 hours in transit).

The Alaska Native Tribal Health Consortium (ANTHC) also provides endocrinology and primary care services to Alaska Native and American Indian patients, and its providers can prescribe Tresiba for eligible beneficiaries. Contact ANTHC at (907) 729-1900 to verify eligibility and scheduling [9].

For patients in the Mat-Su Valley, Kenai Peninsula, or Southeast Alaska without a local endocrinologist, the Alaska Regional Hospital system and Providence Alaska Medical Center both offer telehealth diabetes management referrals. Wait times for in-person endocrinology in Alaska range from 6 to 14 weeks depending on location, which is one reason many patients initiate treatment through a primary care or telehealth provider first.

Prior Authorization for Tresiba in Alaska

Prior authorization (PA) is the most common barrier to accessing Tresiba in Alaska. Most commercial insurers and the federal employee plans covering Alaska state workers require PA before covering Tresiba over a less-expensive basal insulin.

A standard PA submission for Tresiba typically requires the following documentation:

• Current HbA1c (within 90 days)
• Evidence of a trial of at least one formulary-preferred basal insulin (commonly insulin glargine biosimilars such as Basaglar or Semglee) unless contraindicated
• Documentation of hypoglycemia events or hypoglycemia unawareness if switching due to safety concerns
• Prescriber's clinical rationale citing the SWITCH trial data or ADA hypoglycemia guidelines if applicable [5]
• Most recent fasting glucose log or CGM report

Alaska Medicaid does not currently cover Tresiba for type 1 or type 2 diabetes. Patients on Medicaid should ask their provider about Basaglar (insulin glargine biosimilar) or Semglee as formulary alternatives, or apply for the Novo Nordisk Patient Assistance Program [8]. The ADA's insulin access guidance notes that affordability of newer basal insulins remains a documented obstacle to optimal glycemic control, particularly in rural and underserved states [5].

PA approvals in Alaska, once submitted with complete documentation, typically return within 3 to 5 business days through commercial payers. Expedited review (within 72 hours) is available when the prescriber documents urgent clinical need.

Pharmacy Options: Retail, Mail-Order, and 503A Compounding

Retail pharmacies: Anchorage, Fairbanks, and Juneau have Safeway, Fred Meyer (Kroger), and independent pharmacies stocking Tresiba. Stock availability varies by concentration. Call ahead to confirm U-200 availability, as many smaller pharmacies carry only U-100.

Mail-order pharmacies: Express Scripts, CVS Caremark, Optum Rx, and Amazon Pharmacy all ship to Alaska addresses. Standard shipping is 3 to 7 business days. Temperature-controlled packaging is standard for insulin shipments from major mail-order pharmacies, using Phase Change Material (PCM) pouches validated for 72 to 96 hours of temperature control. Insulin exposed to temperatures above 37°C (98.6°F) loses potency; the FDA label specifies that in-use Tresiba pens may be kept at room temperature below 30°C for up to 56 days [1].

503A compounding pharmacies: A 503A-licensed compounding pharmacy in Alaska may compound insulin degludec for a specific patient when there is a documented clinical need, such as an allergy to an excipient in the commercial formulation. The FDA's guidance on compounded insulin analogs notes that 503A pharmacies may compound copies of commercially available insulin analogs only under limited circumstances, and compounded insulin is not FDA-approved [10]. Patients and prescribers should discuss the regulatory and quality-control distinctions before choosing this route. The Alaska Board of Pharmacy maintains a current list of licensed compounding pharmacies at the Alaska DCCED website [11].

Cold-chain delivery to rural Alaska: For patients in villages accessible only by small aircraft or boat, coordination with a regional hub pharmacy such as Tanana Chiefs Conference pharmacy in Fairbanks or the Yukon-Kuskokwim Health Corporation pharmacy in Bethel may be more reliable than national mail-order. Both organizations have established cold-chain protocols for insulin delivery to remote communities [9].

Clinical Monitoring After Starting Tresiba

After the first prescription is filled, the ADA recommends fasting plasma glucose self-monitoring daily during titration, with a target fasting glucose of 80 to 130 mg/dL [5]. A structured titration algorithm often used in practice is to increase the Tresiba dose by 2 units every 3 days until fasting glucose is consistently in target range, or to use the FDA label algorithm of adjusting based on the mean of 3 consecutive fasting glucose values [1].

HbA1c should be rechecked 3 months after initiation. The DEVOTE trial found that patients titrated to a fasting glucose target of 71 to 90 mg/dL on degludec achieved a mean HbA1c reduction of 0.8 percentage points from a baseline mean of 8.4% at 24 weeks [4]. Renal function (eGFR, serum creatinine) warrants monitoring every 6 to 12 months given that insulin clearance is reduced in chronic kidney disease, which can increase hypoglycemia risk [12].

Continuous glucose monitoring (CGM) is increasingly used alongside basal insulin. The ADA 2024 Standards of Care recommend CGM for all adults with type 1 diabetes and for type 2 patients using insulin [5]. Alaska telehealth platforms prescribing Tresiba generally coordinate CGM prescriptions at the same visit, since CGM data substantially improves titration safety and reduces provider callback burden between visits.

The FDA label lists severe hypoglycemia, hypokalemia, and injection-site reactions as the most clinically relevant adverse effects [1]. Patients switching from insulin glargine U-300 to degludec should note that both are ultra-long-acting, and the conversion is generally unit-to-unit; switching from NPH insulin involves a 20% dose reduction per the FDA label to account for improved bioavailability [1].

Cost Reduction Strategies for Alaska Patients

The list price gap between Tresiba and older basal insulins is real, but several pathways reduce out-of-pocket costs substantially.

Novo Nordisk's Tresiba savings card caps monthly cost at $99 for eligible commercially insured patients without income restrictions [8]. Patients must enroll at the Novo Nordisk savings program website and present the card at the pharmacy. The card does not apply to federal programs including Medicare Part D or Medicaid.

For Medicare Part D beneficiaries in Alaska, the Inflation Reduction Act (2022) capped cost-sharing for covered insulin products at $35 per month per covered insulin beginning January 2023 [13]. Tresiba's Part D coverage status varies by plan; patients should use the Medicare Plan Finder tool to confirm formulary status before enrolling in a plan, as switching insulin mid-year is difficult [13].

The Together with Novo Nordisk Patient Assistance Program provides free medication to uninsured or underinsured patients who meet income criteria (generally household income at or below 400% of the federal poverty level) [8]. Applications are available online and typically take 2 to 4 weeks to process. A prescriber signature on the enrollment form is required, and most telehealth platforms can complete this during or after the visit.

GoodRx and similar discount programs can reduce cash-pay cost for Tresiba U-100 to approximately $180 to $250 per package at Anchorage-area pharmacies, depending on current negotiated rates. GoodRx pricing is not guaranteed and fluctuates, so confirm at the point of sale.

Transferring an Existing Tresiba Prescription to Alaska

Patients relocating to Alaska who already have an active Tresiba prescription can transfer it to an Alaska pharmacy under most circumstances. Federal law permits a one-time transfer of a non-controlled-substance prescription between pharmacies across state lines. In practice, the receiving Alaska pharmacy contacts the original pharmacy directly for the prescription record.

The transferred prescription retains its original fill count and expiration date. If refills are exhausted, the Alaska pharmacy will request a new prescription from a licensed Alaska provider, meaning out-of-state prescribers cannot continue writing Tresiba prescriptions for Alaska residents. Scheduling a telehealth visit with an Alaska-licensed prescriber before the last refill runs out avoids a gap in therapy. Most telehealth platforms complete the intake, labs review, and prescription issuance within 3 to 5 business days of the initial appointment request.

Cold-chain integrity during a personal move matters. Unopened Tresiba must remain refrigerated (36°F to 46°F / 2°C to 8°C) during transport. The FDA label specifies that after first use, a Tresiba pen may be kept unrefrigerated at room temperature (below 86°F / 30°C) for up to 56 days, but unopened pens exposed to temperatures above 46°F for extended periods may lose potency before the labeled expiration date [1].